<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>WW International, Inc. (WW)，一家減肥解決方案提供商，週四表示，它現在通過其 Med+ 項目和相關醫療集團提供對禮來的新批准口服 GLP-1 藥物 Foundayo 的訪問，擴展了肥胖或超重人羣的治療選擇。</p>
<p>該公司表示，符合條件的會員可以在獲得經過認證的臨牀醫生支持、保險協助以及其 GLP-1 成功計劃的指導下，使用這種每日一次、無需注射的療法，該計劃在治療前、治療中和治療後提供指導。</p>
<p>WW International 補充説，自費患者的最低劑量價格將從每月 149 美元起，具體費用因劑量而異。</p>
<p>“通過這一新產品，Weight Watchers 正在通過一個值得信賴的平台擴展對 FDA 批准的新選擇的訪問，旨在幫助會員獲得臨牀支持和持續指導，” Weight Watchers 首席商業官 Scott Honken 表示。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

LLYZ

2 倍做多 LLY ETF - Defiance

禮來

WGHTQ

2 倍做多 LLY ETF - Direxion

<p>WW International, Inc. 宣佈將禮來的新批准口服 GLP-1 藥物 Foundayo 納入其 Med+ 計劃。該計劃旨在為肥胖或超重的個體提供更多治療選擇。符合條件的會員可以獲得這種每日一次的治療，以及來自認證臨牀醫生的支持和 GLP-1 成功計劃。自費患者的定價從每月 149 美元起，具體費用根據劑量而異。首席商業官 Scott Honken 強調了這一新產品在為會員提供臨牀支持和指導方面的重要性</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>WW International, Inc. (WW), a weight loss solutions provider, on Thursday said it is now offering access to Eli Lilly and Company's newly approved oral GLP-1 drug Foundayo through its Med+ program and affiliated medical groups, expanding treatment options for people with obesity or overweight.</p>
<div class="lb-trans"><p>WW International, Inc. (WW)，一家減肥解決方案提供商，週四表示，它現在通過其 Med+ 項目和相關醫療集團提供對禮來的新批准口服 GLP-1 藥物 Foundayo 的訪問，擴展了肥胖或超重人羣的治療選擇。</p>
</div><p>The company said eligible members can access the once-daily, injection-free therapy alongside support from board-certified clinicians, insurance assistance and its GLP-1 Success program, which provides guidance before, during and after treatment.</p>
<div class="lb-trans"><p>該公司表示，符合條件的會員可以在獲得經過認證的臨牀醫生支持、保險協助以及其 GLP-1 成功計劃的指導下，使用這種每日一次、無需注射的療法，該計劃在治療前、治療中和治療後提供指導。</p>
</div><p>WW International added that pricing for self-pay patients will start at $149 per month for the lowest dose, with costs varying by dosage.</p>
<div class="lb-trans"><p>WW International 補充説，自費患者的最低劑量價格將從每月 149 美元起，具體費用因劑量而異。</p>
</div><p>&#34;With this new offering, Weight Watchers is expanding access to a new FDA-approved option through a trusted platform built to help members access treatment with clinical support and ongoing guidance,&#34; said Scott Honken, Chief Commercial Officer at Weight Watchers.</p>
<div class="lb-trans"><p>“通過這一新產品，Weight Watchers 正在通過一個值得信賴的平台擴展對 FDA 批准的新選擇的訪問，旨在幫助會員獲得臨牀支持和持續指導，” Weight Watchers 首席商業官 Scott Honken 表示。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

WW 國際將禮來的 GLP-1 Foundayo 納入其 Med+ 計劃